Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: A comparative study with alendronate

British Journal of Pharmacology

Volumn 156, Issue 8, 2009, Pages 1287-1295

  Bitto, A ^b   Burnett, B P ^c   Polito, F ^b   Levy, R M ^c   Marini, H ^d   Stefano, V Di ^b   Irrera, N ^b   Armbruster, M A ^c   Minutoli, L ^b   Altavilla, D ^b   Squadrito, F ^a,b  

^a Section of Pharmacology   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c PRIMUS PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Alendronate; B ALP; CTX; Genistein aglycone; Glucocorticoid induced osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; GENISTEIN; GENISTEIN AGLYCONE; GLUCOCORTICOID; METHYLPREDNISOLONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERAL; BONE STRENGTH; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HISTOPATHOLOGY; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RAT;

ALENDRONATE; ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; FEMALE; FEMORAL FRACTURES; FEMUR; GENISTEIN; INJECTIONS, SUBCUTANEOUS; METHYLPREDNISOLONE; OSTEOPOROSIS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 67849125875     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00100.x     Document Type: Article

References (47)

1. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ et al. (1996). Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow up. J Rheumatol 23 : 995 1000.
2. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E et al. (2001). Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44 : 202 211.
3. Adinoff AD, Hollister JR (1983). Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309 : 265 258.
4. Albertazzi P (2002). Purified phytoestrogens in postmenopausal bone health: is there a role for genistein?. Climacteric 5 : 190 196.
5. Arts J, Kuiper GG, Janssen JM, Gustafsson JA, Lowik CW, Pols HA et al. (1997). Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 138 : 5067 5070.
6. Bitto A, Burnett BP, Polito F, Marini H, Levy RM, Armbruster MA et al. (2008). Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. Br J Pharmacol 155 : 896 905.
7. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP (2001). Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16 : 104 112.
8. Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007). Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18 : 1319 1328.
9. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM (2002). Autocrine activation of glucocorticoids in osteoblasts increase with age and glucocorticoid exposure. J Bone Miner Res 17 : 979 986.
10. Crandall C (2002). Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 162 : 2297 309.
11. Crisafulli A, Altavilla D, Squadrito G, Romeo A, Adamo EB, Marini R et al. (2004). Effects of the phytoestrogen genistein on the circulating /uble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. J Clin Endocrinol Metab 89 : 188 192.
12. Dalle Carbonare L, Bertoldo F, Valenti MT, Zenari S, Zanatta M, Sella S et al. (2005). Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 35 : 645 652 (Review).
13. Devogelaer JP (2006). Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. Rheum Dis Clin North Am 32 : 733 757 (Review).
14. Dolan AL, Koshy E, Waker M, Goble CM (2004). Access to bone densitometry increases general practitioners' prescribing for osteoporosis in steroid treated patients. Ann Rheum Dis 63 : 183 186.
15. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N et al. (2000). Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11 : 331 337.
16. Fuchs RK, Allen MR, Condon KW, Reinwald S, Miller LM, McClenathan D et al. (2008). Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int 19 : 1331 1341.
17. Herrak P, Görtz B, Hayer S, Redlich K, Reiter E, Gasser J et al. (2004). Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 50 : 2327 2337.
18. Horsch K, de Wet H, Schuurmans MM, Allie-Reid F, Cato AC, Cunningham J et al. (2007). Mitogen activated protein kinase phosphatase 1/dual specificity phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol Endocrin 21 : 2929 2940.
19. Iu MF, Kaji H, Sowa H, Naito J, Sugimoto T, Chihara K (2005). Dexamethasone suppresses Smad3 pathway in osteoblastic cells. J Endocrinol 185 : 131 138.
20. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS (2006). Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147 : 5592 5599.
21. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B et al. (2005). Assessment of fracture risk. Osteoporos Int 16 : 581 589 (Review).
22. Kotaniemi A, Piirainen H, Paimela L, Leirisalo-Repo M, Uoti-Reilama K, Lahdentausta P et al. (1996). Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J Rheumatol 23 : 1875 1879.
23. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT et al. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 : 4252 4263.
24. Kung AW, Chan TM, Lau CS, Wong RW, Yeung SS (1999). Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. Rheumatology 38 : 1239 1244.
25. Lajeunesse D, Reboul P (2003). Subchondral bone in osteoarthritis: a biologic link with articular cartilage leading to abnormal remodeling. Curr Opin Rheumatol 15 : 628 633 (Review).
26. Lane NE (2001). An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 27 : 235 253 (Review).
27. Lindsay R, Cosman F (2003) Atlas of Clinical Endocrinology: Osteoporosis. Edited by Stanley Korenman Eric S Orwoll. Current Medicine Group LLC : Philadelphia.
28. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M et al. (2007). Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med 146 : 839 847.
29. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M et al. (2008). OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration. J Bone Miner Res 23 : 715 720.
30. Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N et al. (2002). Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 17 : 1904 1912.
31. Morris HA, Need AG, O'Loughlin PD, Horowitz M, Bridges A, Nordin BEC (1990). Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 46 : 305 308.
32. Natsui K, Tanaka K, Suda M, Yasoda A, Sakuma Y, Ozasa A et al. (2006). High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 17 : 105 108.
33. de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW (2004). Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15 : 589 602 (Review).
34. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA et al. (2004). Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145 : 1835 1841.
35. Patschan D, Loddenkemper K, Buttgereit F (2001). Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 29 : 498 505.
36. Reid IR, Ibbertson HK (1987). Evidence for decreased tubular reabsorption of calcium in glucocorticoid treated asthmatics. Horm Metab Res 27 : 200 204.
37. Riggs BL, Melton LJ III. (1986). Involutional osteoporosis. N Engl J Med 314 : 1676 1686.
38. Ringe JD, Coster A, Meng T, Schacht E, Umbach R (1999). Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 65 : 337 340.
39. Sambrook PN (2007). Anabolic therapy in glucocorticoid-induced osteoporosis. N Engl J Med 357 : 2084 2086.
40. Seeman E, Devogelaer JP, Lorenc R, Spector T, Brixen K, Balogh A et al. (2008). Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23 : 433 438.
41. Soares-Schanoski A, Gómez-Piña V, del Fresno C, Rodríguez-Rojas A, García F, Glaría A et al. (2007). 6-Methylpresi/one down regulates IRAK-M in human and murine osteoclasts and boost bone resorbing activity: a putative mechanism for corticoid induced osteoporosis. J Leukoc Biol 82 : 700 709.
42. van Staa TP (2006). The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79 : 129 137 (Review).
43. van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C (2005). A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98 : 191 198.
44. Tomlinson JW, Bujalska I, Stewart PM, Cooper MS (2000). The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis. Endocr Res 26 : 711 722.
45. Tsugeno H, Tsugeno H, Fujita T, Goto B, Sugishita T, Hosaki Y et al. (2002). Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis. Osteoporos Int 13 : 650 656.
46. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T et al. (2002). Promotion of osteoclast survival and antagonism of bisphosphonate- induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109 : 1041 1048.
47. Woolf AD (2007). An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 19 : 370 375 (Review).